Clinical Classification in Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
Open Access
- 1 September 2016
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 6 (3) , 302-312
Abstract
Congenital heart disease (CHD) is a frequent cause of pediatric pulmonary arterial hypertension (PAH), with diverse etiology and outcome. We aimed to describe phenotypic heterogeneity in pediatric PAH associated with CHD (PAH‐CHD), assess the applicability of the Nice CHD classification, and explore whether this classification accurately reflects patient/disease characteristics and survival. All children with CHD from a contemporary cohort of consecutive pediatric PAH patients followed in three major referral centers (Denver, New York, the Netherlands) were characterized and classified on the basis of the latest proposed clinical classification for PAH‐CHD (World Symposium on Pulmonary Hypertension, Nice, 2013). According to this classification, 24% of 134 children were classified into group 1, 14% into group 2, 19% into group 3, and 30% into group 4; 11% could not be classified. Types of CHD and hemodynamic profile differed between groups, with the highest right atrial pressure in group 4 (P < 0.040). Group 3 children had Down syndrome less frequently (P = 0.011) but other (un)defined syndromes most frequently (P = 0.063) and received most intense PAH‐targeted therapy (P = 0.003). With 15 deaths and one lung transplant (12%; median follow‐up: 4.3 years), survival differences could not be demonstrated between the groups in the Nice CHD classification. Pediatric PAH‐CHD is a heterogeneous condition frequently associated with extracardiac, developmental factors that are believed to affect disease development. The Nice CHD classification identifies groups with specific patient/disease characteristics. However, a substantial proportion of children could not be classified. Group 3 forms a distinct disease entity. Its prognostic value could not be determined because of the low number of events. The Nice CHD classification supports clinical characterization of PAH‐CHD; however, further refinement is needed to classify all children with PAH‐CHD.Keywords
This publication has 33 references indexed in Scilit:
- 46th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, AEPC with joint sessions with the Japanese Society of Pediatric Cardiology and Cardiac Surgery Istanbul, Turkey, May 23–26, 2012Cardiology in the Young, 2012
- Clinical features of paediatric pulmonary hypertension: a registry studyThe Lancet, 2012
- A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011Pulmonary Circulation, 2011
- Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical SettingsThe American Journal of Cardiology, 2010
- Outcome of Pediatric Patients With Pulmonary Arterial Hypertension in the Era of New Medical TherapiesThe American Journal of Cardiology, 2010
- Clinical Characterization of Pediatric Pulmonary Hypertension: Complex Presentation and DiagnosisThe Journal of Pediatrics, 2009
- Pulmonary arterial hypertension in children with congenital heart diseasePVRI Review, 2009
- Congenital heart disease in relation to pulmonary hypertension in paediatric practicePaediatric Respiratory Reviews, 2005
- Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects.Circulation, 1984
- Natural History and Prognosis of Atrial Septal DefectCirculation, 1968